Used in the treatment of acute myeloid leukemia (AML), particularly in patients who have relapsed or are refractory to prior therapy. It functions by reactivating the p53 tumor suppressor pathway, leading to cancer cell death. Currently under investigation in clinical trials, often in combination with other agents like venetoclax to enhance efficacy. Shows promise in targeting leukemia cells while sparing normal cells, offering a potentially more selective therapeutic approach.